Vanda's Late-Stage Trial of Sleep Disorder Drug Meets Primary Goal

Phase 3positivePositive

AI Analysis

Summary

Vanda Pharmaceuticals' late-stage trial of a sleep disorder drug met its primary goal. The positive Phase 3 data represents progress toward potential regulatory submission.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

late-stage trial met primary goal

Importance:7/10

Sentiment:

0.80

clinical trialPhase 3sleep disorderprimary endpoint met

Related Companies

$VNDA

Read the original article

Published by yahoo_finance on September 30, 2026 7:48 AM

Read Original